In a statement released yesterday, the FDA has announced that it is restricting the use of pembrolizumab (Keytruda) and atezolizumab (Tecentriq) for patients with locally advanced or metastatic urothelial cancer who are not eligible for cisplatin-containing therapy.
In a statement released yesterday, the FDA has announced that it is restricting the use of pembrolizumab (Keytruda) and atezolizumab (Tecentriq) for patients with locally advanced or metastatic urothelial cancer who are not eligible for cisplatin-containing therapy.
The FDA made this decision based on data that showed decreased survival associated with each drug as a monotherapy compared with platinum-based chemotherapy in clinical trials that were investigating the drugs ability to treat metastatic urothelial cancer patients who have not received prior therapy and who have low expression of PD-L1.
In 2 ongoing clinical trials, KEYNOTE-361 and IMVIGOR-130, the Data Monitoring Committees’ (DMC) early reviews found patients receiving the drugs as monotherapies with PD-L1 low status had decreased survival compared with patients that received cisplatin or carboplatin-based chemotherapy. In May 2018, the FDA alerted healthcare professionals and oncology clinical investigators to these initial findings.
The trials looked to compare platinum-based chemotherapy combined with either pembrolizumab or atezolizumab to evaluate the efficacy of platinum-based chemotherapy alone. Both drug manufacturers, Merck and Genentech respectively, have stopped enrolling patients whose tumors express low PD-L1 to the monotherapy arms of the trials.
Both pembrolizumab and atezolizumab were approved under the FDA’s accelerated approval pathway to treat urothelial carcinoma patients who are not eligible for cisplatin-containing chemotherapy, regardless of PD-L1 status.
As of last week, pembrolizumab had earned its 11th indication with the approval to treat recurrent or metastatic cervical cancer with disease progression on or after chemotherapy in patients whose tumors express PD-L1. Atezolizumab only holds 1 other indication for the treatment of patients with previously treated metastatic non-small cell lung cancer.
“The FDA has not changed the indications of Keytruda and Tecentriq for the treatment of patients with locally advanced or metastatic urothelial carcinoma who have disease progression during or following any platinum-containing chemotherapy, or within 12 months of neoadjuvant or adjuvant treatment,” the FDA said in a statement.
Preventative Chemotherapy? Not Quite, but Studies Are Underway in Immunoprevention
March 23rd 2024The Princess of Wales is likely referencing adjuvant chemotherapy, but there is a growing field of immunoprevention, which seeks to target precancerous lesions or block heritable cancers.
Read More
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
FDA Grants Accelerated Approval to Liso-Cel for CLL/SLL After BTK, BCL-2 Inhibitors
March 15th 2024The approval fills a void for patients with CLL or SLL whose disease progresses after treatment with a BTK inhibitor and a BCL-2 inhibitor; until now, there has been no standard of care.
Read More